Lumos Pharma Inc (LUMO)

Dec 12, 2024, 8:47 AM EST - 5 weeks ago

Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures' Acquisition of Lumos Pharma

Oct 23, 2024, 3:51 PM EDT - 3 months ago

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Lumos Pharma, Inc.

Oct 23, 2024, 3:31 PM EDT - 3 months ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MMLP and LUMO on Behalf of Shareholders

MMLP

Sep 25, 2024, 4:05 PM EDT - 4 months ago

Lumos Pharma Announces Abstract Accepted for Oral Presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, APPES 2024

Aug 15, 2024, 9:00 AM EDT - 5 months ago

Lumos Pharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference

Aug 1, 2024, 9:30 PM EDT - 6 months ago

Lumos Pharma, Inc. (LUMO) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 4:05 PM EDT - 6 months ago

Lumos Pharma Reports Second Quarter 2024 Financial Results and Provides Clinical Development Update

Jul 23, 2024, 4:05 PM EDT - 6 months ago

Lumos Pharma to Report Second Quarter 2024 Financial Results and Provide Clinical Update on August 1, 2024

May 20, 2024, 4:05 PM EDT - 8 months ago

Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024

May 15, 2024, 3:10 PM EDT - 8 months ago

Lumos Pharma, Inc. (LUMO) Q1 2024 Earnings Call Transcript

May 14, 2024, 4:15 PM EDT - 8 months ago

Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results

May 9, 2024, 2:51 PM EDT - 9 months ago

Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024

Apr 18, 2024, 4:05 PM EDT - 9 months ago

Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings

Mar 20, 2024, 8:00 AM EDT - 10 months ago

Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042

Mar 7, 2024, 5:45 PM EST - 11 months ago

Lumos Pharma, Inc. (LUMO) Q4 2023 Earnings Call Transcript

Mar 7, 2024, 4:01 PM EST - 11 months ago

Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update

Feb 26, 2024, 9:00 AM EST - 11 months ago

Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024

Feb 5, 2024, 4:05 PM EST - 1 year ago

Lumos Pharma to Participate in Oppenheimer's 34th Annual Healthcare Life Sciences Conference

Jan 4, 2024, 4:05 PM EST - 1 year ago

Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer

Nov 21, 2023, 4:15 PM EST - 1 year ago

Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency

Nov 20, 2023, 4:05 PM EST - 1 year ago

Lumos Pharma Announces Participation in the Piper Sandler 35th Annual Healthcare Conference in November

Nov 7, 2023, 4:35 PM EST - 1 year ago

Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates

Nov 7, 2023, 4:01 PM EST - 1 year ago

Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD Met All Primary and Secondary Endpoints

Sep 26, 2023, 9:00 AM EDT - 1 year ago

Lumos Pharma Announces New Data and Analysis of 15 Subjects from OraGrowtH212 Trial Presented at the 2023 ESPE Annual Meeting

Sep 14, 2023, 8:00 AM EDT - 1 year ago

Lumos Pharma Announced Abstract Accepted for Oral Presentation at the European Society for Paediatric Endocrinology Annual Meeting

Sep 7, 2023, 4:34 PM EDT - 1 year ago

Lumos Pharma Announces Participation in Investor Conferences in September

Aug 22, 2023, 9:00 AM EDT - 1 year ago

Independent Panel of Renowned Pediatric Endocrinologists to Discuss Pediatric Growth Hormone Deficiency and the Therapeutic Landscape

Aug 9, 2023, 10:27 PM EDT - 1 year ago

Lumos Pharma, Inc. (LUMO) Q2 2023 Earnings Call Transcript

Aug 9, 2023, 4:01 PM EDT - 1 year ago

Lumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical Update

Jul 26, 2023, 9:00 AM EDT - 1 year ago

Lumos Pharma to Report Second Quarter 2023 Financial Results and Host Conference Call on August 9, 2023

Jul 12, 2023, 8:00 AM EDT - 1 year ago

Lumos Pharma to Participate in the Oppenheimer 2023 Montauk Life Sciences Summit

Jun 28, 2023, 4:01 PM EDT - 1 year ago

Lumos Pharma Announces Departure of Chief Medical Officer

Jun 21, 2023, 9:00 AM EDT - 1 year ago

Lumos to Highlight New LUM-201 Data and Analysis Presented at ENDO 2023 in Virtual KOL Webinar

May 25, 2023, 8:00 AM EDT - 1 year ago

Lumos Pharma Announces Abstracts Accepted for Oral Presentation at 2023 ENDO Meeting with Virtual KOL Event to be Held on June 21st

May 3, 2023, 4:05 PM EDT - 1 year ago

Lumos Pharma Reports First Quarter 2023 Financial Results, Provides Clinical Updates

Apr 27, 2023, 9:00 AM EDT - 1 year ago

Data from Lumos Pharma OraGrowtH Trials to be Presented at Annual Pediatric Endocrine Society Meeting (PES)

Apr 19, 2023, 9:00 AM EDT - 1 year ago

Lumos Pharma to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023

Mar 5, 2023, 2:00 PM EST - 2 years ago

Additional Data on Lumos OraGrowtH Trials Presented at International Meeting of Pediatric Endocrinology

Mar 1, 2023, 9:37 PM EST - 2 years ago

Lumos Pharma, Inc. (LUMO) Q4 2022 Earnings Call Transcript

Mar 1, 2023, 4:05 PM EST - 2 years ago

Lumos Pharma Reports Full Year 2022 Financial Results, Provides Clinical Development Updates

Feb 28, 2023, 4:05 PM EST - 2 years ago

Lumos Pharma Completes Patient Enrollment in Two Phase 2 OraGrowtH Trials Evaluating Oral LUM-201 in Moderate Idiopathic PGHD

Feb 15, 2023, 4:05 PM EST - 2 years ago

Lumos Pharma to Report Full Year 2022 Financial Results and Host Conference Call on March 1, 2023

Jan 3, 2023, 9:00 AM EST - 2 years ago

Lumos Pharma to Participate in 12th Annual LifeSci Partners Corporate Access Event January 9-11, 2023

Dec 12, 2022, 7:30 AM EST - 2 years ago

KOL Review of Lumos Pharma's Interim Phase 2 Data Supports Potential for New Oral Therapeutic Paradigm for Moderate Idiopathic PGHD Patients

Nov 29, 2022, 4:05 PM EST - 2 years ago

Lumos Pharma to Host KOL Webinar to Discuss Interim Phase 2 Data from OraGrowtH Trials in PGHD

Nov 22, 2022, 4:05 PM EST - 2 years ago

Lumos Pharma to Participate in the Piper Sandler 34th Annual Healthcare Conference

Nov 14, 2022, 6:10 AM EST - 2 years ago

Lumos Pharma Reports Third Quarter 2022 Financial Results and Clinical Development Updates

Nov 14, 2022, 6:00 AM EST - 2 years ago

Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral LUM-201 for Moderate Pediatric Growth Hormone Deficiency